(Q38120079)

29 August 2017

title

Nilotinib for treatment of gastrointestinal stromal tumors: out of the equation? (English)

1 reference

29 August 2017

2

Takashi Ishikawa

1 reference

29 August 2017

Tatsuo Kanda

1

1 reference

29 August 2017

Tsuyoshi Takahashi

series ordinal

3

1 reference

29 August 2017

Toshirou Nishida

series ordinal

4

1 reference

29 August 2017

language of work or name

English

0 references

publication date

9 July 2013

1 reference

Expert Opinion on Pharmacotherapy

29 August 2017

published in

1 reference

29 August 2017

volume

14

1 reference

29 August 2017

issue

13

1 reference

29 August 2017

page(s)

1859-1867

1 reference

Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study.

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.816676

10.1517/14656566.2013.816676

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference